Healthcare professional with a pen and tablet.

COVID-19 has changed clinical trials for the better, says Medidata

By Phil Taylor, pharmaphorum

The pandemic forced clinical trial sponsors to change their processes, with a more technology-driven approach and, according to a new study by Medidata, the sector is now “stronger than ever” as a result.

The study, based on interviews conducted earlier this year with 400 clinical trial executives from the UK, France, Germany, and Switzerland, found that more than a third (37%) ranked better outcomes of trials within the top three areas of improvement since COVID-19 emerged.

Meanwhile, 36% said recruitment and enrolment of subject into trials were also improved, with patients reporting better experiences with participation, and almost all (99.7%) thought that all or some improvements to the clinical trial process as a result of the pandemic will be here to stay.

Among the changes, were greater use of decentralised clinical trials (DCTs), which were a major factor in allowing clinical research to continue during the early stages of the pandemic, aided by technologies that allowed patients to take part in their own homes.

The result has been “a more streamlined and efficient operating model, with the patient at the centre,” according to the report. Read more …